Sun Pharma expects high single-digit top-line growth in FY23
"R&D investments are expected to be between 7-8 per cent of sales next year," Shanghvi noted.
New Delhi: Drug major Sun Pharma on Monday said it expects high single-digit top-line growth in the current financial year with all its business verticals well placed to lead the charge. The company, which posted revenues of Rs 38,426 crore in FY22, aims to invest 7-8 percent of sales in the R&D front in the ongoing fiscal."We expect high single-digit top-line growth for FY23. All...
New Delhi: Drug major Sun Pharma on Monday said it expects high single-digit top-line growth in the current financial year with all its business verticals well placed to lead the charge. The company, which posted revenues of Rs 38,426 crore in FY22, aims to invest 7-8 percent of sales in the R&D front in the ongoing fiscal.
Read also: Sun Pharma gets 10 USFDA observations for Halol facility
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd